Could the vast amounts of secondary funds raised recently and the limited deal completion lead to a capital overhang in the coming years? Francois Rowell asks Sergio Jovele of Partners Group, which yesterday announced the closing of its latest secondaries-focused vehicle on EUR 2.5bn.
Also backing the biotech startup were the Zürcher Kantonalbank and Greencross Medical Science Corp
Company plans to use the fresh capital to further expand, develop new features and scale up its team
EVentures, 468 Capital and HV Holtzbrinck back the round for the climate change mitigation app
Clessidra has been in negotiations for the acquisition of the Italian wine producer since February 2020